This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Meaning for Extended Release

For a drug that Pfizer (PFE - Get Report) says will be an important addition to its arsenal, Lyrica is getting a slow release in the U.S.

The drug was approved by the Food and Drug Administration on Monday as an add-on treatment for epilepsy, but Pfizer says the product won't be available until this fall. Lyrica also was approved by the FDA in December as a treatment for pain associated with shingles and for nerve pain associated with diabetes. At the time, Pfizer said the drug would reach the market "in the near future."

The drug isn't on the market for any of the FDA-approved uses because it has been declared a controlled substance and must be reviewed and classified by the Drug Enforcement Administration. Rebecca Hamm, a Pfizer spokeswoman, said Monday the company hopes to get the lowest of five DEA classifications, meaning the drug has the least chance for abuse or misuse.

But the DEA hasn't made a decision, and it can take many months to classify a controlled substance. For example, it took nearly four months for the DEA to sign off on the sleep drug Lunesta from Sepracor (SEPR) before the drug became available in the U.S. in early April.

Lyrica has been viewed by Pfizer as a successor to Neurontin, which had $2.73 billion in sales last year and which is under ferocious attack by generic competitors. Neurontin is approved for seizures and for pain associated with shingles.

During the first quarter of 2005, Neurontin recorded $182 million in worldwide sales, down 74% from the same quarter last year. The U.S. component fared worse: first-quarter 2005 sales dropped 90% to $56 million.

Meanwhile, Lyrica produced only $20 million in revenue during the first quarter of 2005, thanks to foreign market sales. Analysts say Lyrica has several advantages over Neurontin -- it can treat more diseases, it's more potent, it has fewer interactions with other drugs, and it's easier to take.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PFE $29.12 1.90%
AAPL $95.08 0.07%
FB $99.61 -0.14%
GOOG $678.22 -0.66%
TSLA $148.17 0.12%


Chart of I:DJI
DOW 16,015.88 -11.17 -0.07%
S&P 500 1,852.68 -0.76 -0.04%
NASDAQ 4,273.1550 -10.5980 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs